Definitive Contract HHSN272201500027C

This is a fixed-price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Pulmokine, Inc. for the development of "Aerosolized Delivery of Anti-Tubercular Drugs." The contract has a ceiling value of $224,960.00 and a period of performance ending on January 15, 2016. As an SBIR Phase I contract, this award supports early-stage research and...

<p>The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $224,881.00 Firm Fixed Price contract to Keystone Nano Inc., a Small Disadvantaged Business, for the &quot;DEVELOPMENT OF SIRNA NANOJACKETS FOR RNAI-BASED INFLUENZA TREATMENT&quot; under the Small Business Innovation Research (SBIR) Program Phase I. The contract has a completion date of January 31, 2017. This award is a Definitive Contract and is set aside for small business.</p>

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Kitware Inc., a small business S corporation located in Clifton Park, New York. The contract has a ceiling value of $299,999 and is a definitive, firm-fixed-price contract with a completion date of September 5, 2025. The contract is not set aside for a specific business type. The contract involves research and development work,...

This is a $299,208 firm fixed price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian federal agency, to John Snow Labs Inc., a self-certified small disadvantaged business. The contract is for SBIR Topic 135, with a period of performance through September 4, 2025. The contract does not have a set-aside designation. As an SBIR (Small Business Innovation Research) contract, it is part of a larger SBIR program managed by NIAID to fund research and...

This federal contract award, valued at $210,507.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to PAI Life Sciences Inc., a self-certified small disadvantaged business, for the &quot;AEROSOLIZED DELIVERY OF ANTI-TUBERCULAR DRUGS&quot; project. The contract is a Definitive Contract with a Firm Fixed Price pricing type. PAI Life Sciences will be the prime contractor, and Research Triangle Institute (RTI International), a non-profit research organization, will...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. government. The contract, with a ceiling value of $299,943.00, has been awarded to Lifetime Omics, Inc., a minority-owned, woman-owned, and small disadvantaged business. The contract is for research related to SBIR Topic 123, with a completion date of November 30, 2024. The contract is a definitive contract with a firm...

This is a $300,000 Firm Fixed Price contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Vitruvian Bio, LLC, a small disadvantaged woman-owned business. The contract is for a Small Business Innovation Research (SBIR) Phase I project to be completed by June 30, 2023. The award is associated with a larger SBIR solicitation that sought innovative research proposals from small businesses to...

This is a $4,590,862.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Sorrento Therapeutics, Inc., a small disadvantaged business. The contract is for the &quot;DEVELOPMENT OF IN VITRO FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES&quot;, which was a Broad Agency Announcement (BAA) research area. The contract has a period of performance through May 2, 2025...

This is a Firm Fixed Price contract awarded by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) to Techwave International, Inc., a self-certified small disadvantaged business. The contract is part of the Small Business Innovation Research (SBIR) program under Topic Area 045, with a potential value of $224,689.92. The contract does not have a set-aside designation and was awarded on May 5, 2017, with a completion date of July 31, 2018. The...

This contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Qrumpharma, Inc., a self-certified small disadvantaged business, for a Small Business Innovation Research (SBIR) Program Phase I project. The objective is to determine the feasibility of a clofazimine inhalation formulation for preclinical development in tuberculosis. The contract is a definitive contract with a firm...